Endpoints and clinical trial design for nonalcoholic steatohepatitis. - Wikidata - thesis-toulmin - TriplyDB

Endpoints and clinical trial design for nonalcoholic steatohepatitis.

Endpoints and clinical trial design for nonalcoholic steatohepatitis.

http://www.wikidata.org/entity/Q33583798

about

Non-alcoholic fatty liver disease: what the clinician needs to know.Insulin resistance in development and progression of nonalcoholic fatty liver disease Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future Molecular regulation of miRNAs and potential biomarkers in the progression of hepatic steatosis to NASH Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway Obesity: physiologic changes and implications for preoperative management Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults.Vitamin E and nonalcoholic fatty liver disease Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?Transitions of histopathologic criteria for diagnosis of nonalcoholic fatty liver disease during the last three decades Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial Serum Alanine Aminotransferase Trends and Their Relationship with Obesity and Metabolic Syndrome in United States Adolescents, 1999-2014.Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis.Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease.Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma.TRIF Differentially Regulates Hepatic Steatosis and Inflammation/Fibrosis in Mice Prevalence of Nonalcoholic Fatty Liver Disease and its Related Metabolic Risk Factors in Isfahan, Iran Non-alcoholic fatty liver disease: An expanded review Monitoring the efficacy of omega-3 supplementation on liver steatosis and carotid intima-media thickness: a pilot study.Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile.Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations.Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease.Prevalence and outcome of non-alcoholic fatty liver disease in adolescents and young adults undergoing weight loss surgery.Circulating microRNAs in patients with non-alcoholic fatty liver disease Serum alanine aminotransferase as a biomarker of treatment response in nonalcoholic steatohepatitis.The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis.Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis.Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis Soluble CD14 levels reflect liver inflammation in patients with nonalcoholic steatohepatitis.LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study.OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease.Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet.Practical approach to non-alcoholic fatty liver disease in patients with diabetes.Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis.Obstructive Sleep Apnea Is Associated with Nonalcoholic Steatohepatitis and Advanced Liver Histology.

P2860

Q24563068-D05F72E7-6E8E-4827-B8D6-33616537A4B2 Q26748687-50466D9E-C391-4FA3-9389-AB95BBD11AE3 Q26777658-A42FAE5E-88C8-4195-AAA7-8E879AE5E982 Q26778376-62938D20-846E-49B8-AB03-F8CDC2CC9066 Q26780252-E749B87C-BA61-4919-92FD-61D3557BC105 Q26800894-04ACD3DB-85DB-4F54-87C3-83EEA0BD4D19 Q26830911-27B53E3A-CDCF-4A22-81CB-4840B594DC5F Q26992163-1B94DDC0-57C8-4C0B-9E4C-0CE04596B2D7 Q26998093-80DB0C5B-85DE-497F-B1AA-2E5DC41E5FC9 Q27302142-137B63D7-9199-4FE2-A7B3-52C14FC31B70 Q27693883-31724B32-A8D3-419C-B7F8-9DAD707B8F57 Q28079445-B5DD7299-DF1A-49D9-B3EB-DB17CA79C84B Q28088798-C4D22540-717F-41C5-8B4A-9B8A49286F02 Q28607750-31C78B81-9C69-4C6C-8098-CB7139365028 Q28661700-28CB1D0D-EBF9-4C06-88DC-822943A35E8E Q30252383-576DB843-24E8-4F63-BEC9-77EFA22179E7 Q30412709-4459A339-CE84-4580-9844-FF343F6C199B Q30433234-BEF6CF71-2FBF-470E-9C8D-134204CCF7F4 Q30577903-5A801EE5-AE32-4CAD-82CA-9169ADE0B7E5 Q33554179-D21A57D3-F298-4015-8C1F-2A219A7F5EC3 Q33600346-BDE4F6BE-C342-41F9-9F70-B1BAB231D4EE Q33630744-5D9475E3-E5AD-4F0D-9704-423D6C7832F2 Q33789868-6E9A5023-7329-452D-82D2-FD3DD161D5AA Q33819770-D8C913DF-6A97-4CA9-85A3-D29DB402E891 Q33820345-C937E352-1B98-4A85-A932-2F2F96A65841 Q33948324-8B23556D-882C-42C7-AF5B-B34B81192475 Q34009053-68664048-4E23-4953-ACE7-533B048D077F Q34175430-2DC49BF2-2083-4576-B5D1-5B88AB5CD86D Q34179239-90A1965F-28C2-461B-8416-C8EDDC670F4C Q34225038-38BE8840-A3D3-4B27-B363-71B4E63713C6 Q34252404-127BD795-DB08-473C-B8AD-31BC1046B12C Q34310464-98C820BC-C1C0-4825-B7A7-A6808E380063 Q34499029-4EFD67A0-8B13-4D7B-8D68-2095A49284D0 Q34769697-ADA413C8-5309-4E40-8568-B90CCA800421 Q34776084-6BB8781F-4D4E-4AC4-9D11-7FD6C276E270 Q34788743-15C403B6-E0E9-477C-A6D5-D7D8AB2CD730 Q34796362-02FAF923-3B8D-42D5-8082-4C312F809929 Q35561693-58661FB2-01E8-47AD-8BD3-472CB7B1F990 Q35676997-34069846-3EAE-484B-8D85-6B481A7F4D8B Q35843452-7E7AA544-BEDE-4E24-844C-66F069F31B4C

P2860

Endpoints and clinical trial design for nonalcoholic steatohepatitis.

http://www.wikidata.org/entity/Q33583798

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Endpoints and clinical trial design for nonalcoholic steatohepatitis.

@ast

Endpoints and clinical trial design for nonalcoholic steatohepatitis.

@en

Endpoints and clinical trial design for nonalcoholic steatohepatitis.

@nl

type

label

Endpoints and clinical trial design for nonalcoholic steatohepatitis.

@ast

Endpoints and clinical trial design for nonalcoholic steatohepatitis.

@en

Endpoints and clinical trial design for nonalcoholic steatohepatitis.

@nl

prefLabel

Endpoints and clinical trial design for nonalcoholic steatohepatitis.

@ast

Endpoints and clinical trial design for nonalcoholic steatohepatitis.

@en

Endpoints and clinical trial design for nonalcoholic steatohepatitis.

@nl

P1433

Q33583798-87011704-A648-49D7-A19E-736FE7514DEB

P1476

Q33583798-A3E1442E-1DF3-4D09-8988-DCFA8CA36BA8

P2093

Q33583798-016E0BB9-4F80-463A-AAEB-B3E3F01E4FCC

Q33583798-089822CD-7DFD-42C7-BC6D-C60793C04099

Q33583798-6C05A7C9-C728-41EA-8D02-714BCB8B6B99

Q33583798-91435139-E5FA-439F-9EA4-D9FC16BBED40

Q33583798-9D59346D-F71D-4DEA-976D-6CF619417108

Q33583798-CC973E19-DF73-475E-ADCA-3C0308CA25E0

Q33583798-CDE84A80-DB8A-4734-BD86-DE8ECCD28B9C

P2860

Q33583798-1048453F-C95B-4583-A733-415DFE5854DE

Q33583798-129BBE0E-A32B-4374-BE74-C206713A4EB9

Q33583798-13FC97E6-1D61-42E5-BAAB-69A0386D5C5D

Q33583798-18C59731-9AE8-41FD-B6EA-4E89FE5446BE

Q33583798-1E0409C8-D919-49D5-A587-0180362BA4A6

Q33583798-284A1189-20C8-42DE-9382-D37A210A2051

Q33583798-289FA7D1-70FF-45B3-BE7D-4ABC7C02B7CE

Q33583798-2D0F2694-8E30-4462-B1F0-C506EC069DEA

Q33583798-33DD448B-56F6-4AE0-B284-982DFF5B2AE7

Q33583798-3548E8B0-2CC3-49F4-AA3E-8FA98405099C

P304

Q33583798-77C83D6F-0896-4099-B629-99B76A88B3C5

P31

Q33583798-85F3713B-9D1B-43F3-9464-B1FA48EDFDAE

P356

Q33583798-8C29F8CF-5544-4E70-A7D4-64F34FD59596

P407

Q33583798-DE5F4C05-0B9E-4E40-8896-69CA5D8D2170

P433

Q33583798-70E37F49-DA3C-4C95-B46F-70E0AC61645F

P478

Q33583798-0C663561-EBF2-4A79-A01E-875F0A4B6D5C

P50

Q33583798-56EF4C0A-F992-4E67-B9D2-0F8F131B619A

P577

Q33583798-934DB529-A396-48BA-B410-ECEA5FE06DE4

P5875

Q33583798-20B971FD-E7F6-4F05-AAA2-84B8DAC53BC3

P698

Q33583798-2E303CAF-3E20-4937-B156-435E0D9163F9

P921

Q33583798-83B1F1FD-3D2E-4190-A394-1E7632114391

P932

Q33583798-464E2E9C-CB29-4835-B388-4C3F68CA2CB2

P356

P1433

P1476

Endpoints and clinical trial design for nonalcoholic steatohepatitis.

@en

P2093

Arthur McCullough

http://www.w3.org/2001/XMLSchema#string

Arun J Sanyal

http://www.w3.org/2001/XMLSchema#string

Elizabeth M Brunt

http://www.w3.org/2001/XMLSchema#string

Joel E Lavine

http://www.w3.org/2001/XMLSchema#string

Kris V Kowdley

http://www.w3.org/2001/XMLSchema#string

Naga Chalasani

http://www.w3.org/2001/XMLSchema#string

Vlad Ratziu

http://www.w3.org/2001/XMLSchema#string

P2860

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

Long-term follow-up of patients with NAFLD and elevated liver enzymes

NASH and cryptogenic cirrhosis: a histological analysis.

Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

P304

344-353

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.24376

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P50

David E. Kleiner

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51077131

http://www.w3.org/2001/XMLSchema#string

P698

21520200

http://www.w3.org/2001/XMLSchema#string

P921

Steatohepatitis

P932

4014460

http://www.w3.org/2001/XMLSchema#string